nivolumab
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic Hepatocellular Carcinoma
The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for ...
APRIL 23, 2025
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
The FDA has approved nivolumab with ipilimumab for adult and pediatric patients 12 years of age and older with ...
APRIL 16, 2025
New First-Line Option for Highly Mutated CRC?
The dual immunotherapy combination of nivolumab plus ipilimumab reduced the risk for disease progression or death ...
MARCH 12, 2024
FDA Grants New Indication for Opdivo for Resected Esophageal or GEJ Cancer
The FDA granted a new indication for nivolumab (Opdivo, Bristol Myers Squibb) for the treatment of patients with ...
JUNE 7, 2021
Opdivo Approved for First-Line Treatment of Advanced or Metastatic GI Cancers
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb), in combination with fluoropyrimidine- and ...
APRIL 27, 2021